Active Pharmaceutical Ingredients (API) Global Market - Forecast to 2025

Publishing Date : May, 2019
Report Code : HCPH 0100
Price:
Single license $5,400
Site license $7,200
Global license $9,000


Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having direct effect on disease treatment. APIs are synthesized by chemical synthesis, fermentation, biotechnological methods or enhanced from natural source. According to IQ4I analysis, the global Active Pharmaceutical Ingredient market is expected to grow at a high CAGR to reach $307.2 billion by 2025. Adoption of biologics in disease management and increasing regulatory approvals in the past year, increasing scope of HPAPI market, patent expiration of major drugs, increasing trend of outsourcing and increase in geriatric population are some of the factors driving the market growth. The global API market is mainly segmented by synthesis, by business type, by application and by geography.

API market based on synthesis is further divided into synthetic API, Biotech API and HPAPI. Synthetic API holds major share in 2018 and is expected to grow at a mid single digit CAGR from 2018 to 2025. The major factors driving the synthetic chemical API market are patent expiration of synthetic (small molecule drugs), increasing number of small molecules in clinical trials, increasing outsourcing by the pharmaceutical companies, CMOs investments to expand manufacturing facilities, rise in incidence of chronic and age-related diseases, rapid growth in oncology market, technological advancement like cryogenic and continuous flow manufacturing. Based on the customer, the synthetic API is further divided into branded API and generic API. Branded API accounted the largest share in 2018 and is expected to grow at a mid single digit CAGR from 2018 to 2025. Generic API is expected to grow at a high single digit CAGR from 2018 to 2025, due to Patent expiry of blockbuster drugs, rising healthcare expenses, increasing outsourcing and shift towards the generic medicines led by the government initiatives.

Biotech API is expected to grow at a high single digit CAGR from 2018 to 2025. Increased investment in R&D by pharmaceutical companies for developing biologic drugs, adoption of biological therapies in disease management, increasing outsourcing, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses, increasing number of branded drugs going off-patent creating a scope for biosimilars, requirement of novel biologics therapeutics for rare diseases, increasing demand for antibody conjugates are few factors driving the biotech API market. Biotech API is further segmented into monoclonal antibodies, recombinant proteins, vaccines and others (stem cell therapy and gene therapy). Monoclonal antibodies accounted for highest share in 2018 and expected to grow at a double digit CAGR from 2018 to 2025. Development of next generation antibodies such as antibody-drug conjugates and rising venture capital investments and applications of monoclonal antibodies are the factors booming monoclonal antibodies market growth. Based on the customer, biotech API is further divided into biologics and biosimilars. Biologics accounted the largest share in 2018 and is expected to grow at a high single digit CAGR from 2018 to 2025. Biologics market is driven globally due to adoption of biological therapies in disease management, increasing biologics approvals in the past year, increasing chronic and autoimmune illnesses and increasing elderly population globally. Biosimilars is expected to grow at a mid double digit CAGR from 2018 to 2025. Factors driving the biosimilar drug market are patent expiry of biological drugs, low cost compared to biologics health care expenditure, increase in chronic diseases, growing geriatric population, demand for quality healthcare.

HPAPI is expected to grow at a high single digit CAGR from 2018 to 2025. Rapid growth in oncology market, low toxicity and lower side effects, technological advancements in HPAPI, increasing outsourcing, increasing incidence of chronic and age related diseases are few factors driving the HPAPI market growth. Based on customer, HPAPI is further divided into branded API and generic API. Branded API is accounted the largest share in 2018 and is expected to grow at a high single digit CAGR from 2018 to 2025, increased development of targeted therapy APIs, increased investments in the manufacturing of branded HPAPI are the factors driving the market. Generic API is expected to grow at a high single digit CAGR from 2018 to 2025. Patent expiry of blockbuster drugs, rising healthcare expenses and shift towards the generic medicines led by the government initiatives are some of the factors driving the generic HPAPI market.

By business type, global API market is divided into captive API and merchant API. Captive market holds major share in 2018 and is expected to grow at a mid single digit CAGR from 2018 to 2025, captive API is further divided into branded captive API and generic captive API, branded captive API accounted the largest share in 2018 and is expected to grow at a mid single digit CAGR from 2018 to 2025. Merchant API market is fastest growing segment with a high single digit CAGR from 2018 to 2025. Novel drugs patent expiry, high cost of innovative drugs and complications in innovative drug manufacturing are some of the factors driving the growth of Merchant API market. Merchant API market is further divided into branded merchant API and generic merchant API. Generic merchant API accounted the largest share in 2018 and is expected to grow at a double digit CAGR from 2018 to 2025. Increasing outsourcing, advanced manufacturing facilities, lack of in-house manufacturing capability, high capital investment and cost of API manufacturing are the factors driving Merchant API market.

By therapeutic applications, API market is segmented into infectious diseases, oncology, cardiovascular disorders, central nervous system, pulmonary disorder, gastrointestinal disorder, endocrine disorders, metabolic disorders, genito-urinary disorders, musculo-skeletal disorders and others. In application segment, Oncology holds major share in 2018 and expected to grow at a high single digit CAGR from 2018 to 2025. In synthetic API, infectious diseases accounted the largest share in 2018 and is expected to grow at a high single digit CAGR from 2018 to 2025, oncology is expected to grow at a high single digit CAGR from 2018 to 2025. In biotech API, musculoskeletal disorders accounted the largest share in 2018 and is expected to grow at a high single digit CAGR from 2018 to 2025, oncology is expected to grow at a double digit CAGR from 2018 to 2025. In HPAPI, oncology accounted the largest share in 2018 and is expected to grow at a high single digit CAGR from 2018 to 2025. Biotech API and HPAPI is driving the market growth at faster pace due to rising targeted therapy demand in last 15 years for treatment of diseases mainly in oncology sector.

Active pharmaceutical Ingredients market by region is segmented as North America, Europe, Asia-Pacific and Rest of the world (ROW) where North America holds largest share in 2018 and is expected to grow at a high single digit CAGR from 2018 to 2025. Patent expiration of the major drugs, rising demand for biotech APIs from government and private companies, market entry of biosimilars, increasing scope of high potent drugs and increase in the prevalence of chronic diseases such as cancer, musculoskeletal disorder, cardiac disease are some of the major factors driving the North America API market. Asia-Pacific region is expected to grow at a high single digit CAGR from 2018 to 2025. Low labor cost, abundance availability of raw materials, infrastructure facility, rise in generic drugs demand, increased production capabilities, the presence of large number of domestic and international players, and concentration of CMO companies are some of the factors that are driving the market growth.

Some of the key players of Active pharmaceutical Ingredient (API) market are Lonza Group (Switzerland), Boehringer Ingelheim GmbH (Germany), Teva Pharmaceutical Industries LTD (Israel), Sanofi (France), Patheon N.V (U.S), Aurobindo pharmaceuticals. (India), Seigfried Holdings A.G (Switzerland), Olon S.p.A (Italy), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), Cambrex Corporation (U.S.) and AMRI, (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Italy
  • Germany
  • France
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • Middle East and Others
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     ADOPTION OF BIOLOGICS IN DISEASE MANAGEMENT AND INCREASING REGULATORY APPROVALS IN THE PAST YEAR
        • 3.3.1.2     INCREASING SCOPE OF HPAPI MARKET
        • 3.3.1.3     PATENT EXPIRATION OF MAJOR DRUGS
        • 3.3.1.4     INCREASING TREND OF OUTSOURCING
        • 3.3.1.5     INCREASE IN GERIATRIC POPULATION
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     CONTAMINATION OF API
        • 3.3.2.2     FIERCE COMPETITION BETWEEN API PLAYERS
        • 3.3.2.3     HIGH COST FOR MANUFACTURING APIS
        • 3.3.2.4     REQUIREMENT OF HIGHLY SKILLED TECHNICIANS
        • 3.3.2.5     STRINGENT REGULATORY POLICIES AND ENVIRONMENTAL CONCERNS
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.1.2     ISO 13408 ASEPTIC PROCESSING
        • 3.4.1.3     ISO 14644-1 CLEAN ROOM STANDARDS
      • 3.4.2     U.S.
      • 3.4.3     CANADA
      • 3.4.4     MEXICO
      • 3.4.5     EUROPE
      • 3.4.6     CHINA
      • 3.4.7     INDIA
      • 3.4.8     JAPAN
      • 3.4.9     AUSTRALIA
      • 3.4.10     SOUTH KOREA
      • 3.4.11     LATIN AMERICA
      • 3.4.12     MIDDLE EAST
    • 3.5     TECHNOLOGICAL ADVANCEMENTS
      • 3.5.1     INTRODUCTION
      • 3.5.2     AUTOMATION AND CONTROL
      • 3.5.3     CONTINUOUS MANUFACTURING
      • 3.5.4     CRYOGENIC TECHNOLOGY
      • 3.5.5     SINGLE - USE SYSTEM (SUS)
      • 3.5.6     MAMMALIAN CELL BASED PRODUCTION
    • 3.6     PORTER’S FIVE FORCE ANALYSIS
      • 3.6.1     THREAT OF NEW ENTRANTS
      • 3.6.2     THREAT OF SUBSTITUTES
      • 3.6.3     BARGAINING POWER OF SUPPLIERS
      • 3.6.4     BARGAINING POWER OF BUYERS
      • 3.6.5     COMPETITIVE RIVALRY
    • 3.7     SUPPLY CHAIN ANALYSIS
    • 3.8     MARKET SHARE ANALYSIS
    • 3.9     API MANUFACTURING UNITS
    • 3.10     GLOBAL PHARMACEUTICAL API PRODUCTION VOLUME
    • 3.11     PATENT EXPIRY AND ANDA APPROVALS
    • 3.12     COMPANIES ACQUISITION, MERGER AND EXPANSIONS
    • 3.13     COLLABORATION AND AGREEMENT BETWEEN API MANUFACTURERS
    • 3.14     SELECTED TOP SELLING API
    • 3.15     API MANUFACTURERS REVENUE AND CAPABILITIES TABLE
  • 4     API GLOBAL MARKET, BY SYNTHESIS
    • 4.1     INTRODUCTION
    • 4.2     SYNTHETIC API
      • 4.2.1     SYNTHETIC API BY CUSTOMER BASE
        • 4.2.1.1     BRANDED SYNTHETIC API
        • 4.2.1.2     GENERIC SYNTHETIC API
    • 4.3     BIOTECH API
      • 4.3.1     INTRODUCTION
        • 4.3.1.1     MONOCLONAL ANTIBODIES
        • 4.3.1.2     RECOMBINANT PROTEINS
        • 4.3.1.3     VACCINES
        • 4.3.1.4     OTHERS
      • 4.3.2     BIOTECH API BY CUSTOMER BASE
        • 4.3.2.1     BIOLOGIC API
        • 4.3.2.2     BIOSIMILAR API
    • 4.4     HPAPI
      • 4.4.1     HPAPI BY CUSTOMER BASE
        • 4.4.1.1     BRANDED HPAPI
        • 4.4.1.2     GENERIC HPAPI
  • 5     API GLOBAL MARKET, BY BUSINESS TYPE
    • 5.1     INTRODUCTION
    • 5.2     CAPTIVE API BY TYPE
      • 5.2.1     BRANDED CAPTIVE API
      • 5.2.2     GENERIC CAPTIVE API
    • 5.3     MERCHANT API BY TYPE
      • 5.3.1     BRANDED MERCHANT API
      • 5.3.2     GENERIC MERCHANT API
  • 6     API GLOBAL MARKET, BY APPLICATION
    • 6.1     INTRODUCTION
    • 6.2     INFECTIOUS DISEASES
    • 6.3     ONCOLOGY
    • 6.4     CARDIOVASCULAR DISORDERS
    • 6.5     CENTRAL NERVOUS SYSTEM
    • 6.6     PULMONARY DISORDERS
    • 6.7     GASTROINTESTINAL DISORDERS
    • 6.8     ENDOCRINE DISORDERS
    • 6.9     METABOLIC DISORDERS
    • 6.10     GENITOURINARY DISORDERS
    • 6.11     MUSCULOSKELETAL DISORDERS
    • 6.12     OTHER APPLICATIONS
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     ITALY
      • 7.3.2     GERMANY
      • 7.3.3     FRANCE
      • 7.3.4     REST OF EUROPE
    • 7.4     APAC
      • 7.4.1     CHINA
      • 7.4.2     JAPAN
      • 7.4.3     INDIA
      • 7.4.4     REST OF APAC
    • 7.5     ROW
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATAM
      • 7.5.3     MIDDLE EAST & OTHERS
  • 8     COMPETITIVE LANDSCAPE
    • 8.1     INTRODUCTION
    • 8.2     EXPANSIONS
    • 8.3     APPROVALS
    • 8.4     ACQUISITIONS
    • 8.5     AGREEMENTS AND COLLABORATION
    • 8.6     OTHERS
  • 9     MAJOR COMPANIES
    • 9.1     ALBANY MOLECULAR RESEARCH INC.
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     AUROBINDO PHARMA LIMITED
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     BOEHRINGER INGELHEIM GMBH
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     CAMBREX CORPORATION
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     DIVIS LABORATORIES
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     GLAXOSMITHKLINE PLC
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     LONZA GROUP LTD.
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     OLON S.P.A.
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     THERMO FISHER SCIENTIFIC (PATHEON N.V.)
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     PFIZER INC.
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS
    • 9.11     SANOFI
      • 9.11.1     OVERVIEW
      • 9.11.2     FINANCIALS
      • 9.11.3     PRODUCT PORTFOLIO
      • 9.11.4     KEY DEVELOPMENTS
      • 9.11.5     BUSINESS STRATEGY
      • 9.11.6     SWOT ANALYSIS
    • 9.12     SIEGFRIED HOLDING AG
      • 9.12.1     OVERVIEW
      • 9.12.2     FINANCIALS
      • 9.12.3     PRODUCT PORTFOLIO
      • 9.12.4     KEY DEVELOPMENTS
      • 9.12.5     BUSINESS STRATEGY
      • 9.12.6     SWOT ANALYSIS
    • 9.13     TEVA PHARMACEUTICALS INDUSTRIES LIMITED
      • 9.13.1     OVERVIEW
      • 9.13.2     FINANCIALS
      • 9.13.3     PRODUCT PORTFOLIO
      • 9.13.4     KEY DEVELOPMENTS
      • 9.13.5     BUSINESS STRATEGY
      • 9.13.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 2     GLOBAL SMALL MOLECULE API REVENUE ($MN), AVERAGE SELLING PRICE ($/KG) AND PRODUCTION IN TONS, BY APPLICATION (2018)
      • TABLE 3     GLOBAL SMALL MOLECULE VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2017-2025) (MILLION LITRES)
      • TABLE 4     GLOBAL SMALL MOLECULE API PRODUCTION, BY APPLICATION, (2017-2025) (TONS)
      • TABLE 5     GLOBAL BIOLOGICS VOLUME AND UTILIZATION, CMO VOLUME AND UTILIZATION, (2017-2025) (MILLION LITRES)
      • TABLE 6     GLOBAL SMALL MOLECULE API PRODUCTION, (2017-2025) (METRIC TONS)
      • TABLE 7     GLOBAL BIOLOGICS API PRODUCTION, (2017-2025) (METRIC TONS)
      • TABLE 8     GLOBAL API PRODUCTION, (2017-2025) (METRIC TONS)
      • TABLE 9     PATENT EXPIRY OF SYNTHETIC API DRUGS, (2016 – 2021)
      • TABLE 10     PATENT EXPIRY OF BIOTECH API DRUGS, (2017 – 2018)
      • TABLE 11     ANDA APPROVALS: SMALL MOLECULES - GENERICS, (2017 – 2028)
      • TABLE 12     ANDA APPROVALS: BIOSIMILARS, (2016 – 2018)
      • TABLE 13     COMPANIES ACQUISITION, MERGER AND EXPANSIONS, (2017 – 2019)
      • TABLE 14     EXPANSIONS, (2016 – 2018)
      • TABLE 15     COLLABORATIONS AND AGREEMENTS, (2017 – 2018)
      • TABLE 16     API GLOBAL MARKET REVENUE, BY SYNTHESIS, (2017-2025) ($MN)
      • TABLE 17     API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 18     SYNTHETIC API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 19     SYNTHETIC API GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 20     BRANDED SYNTHETIC API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 21     GENERIC SYNTHETIC API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 22     BIOTECH API GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2017-2025) ($MN)
      • TABLE 23     BIOTECH API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 24     MONOCLONAL ANTIBODIES GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 25     RECOMBINANT PROTEINS GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 26     VACCINES GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 27     OTHER BIOTECH API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 28     BIOTECH API GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 29     BIOLOGIC API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 30     BIOSIMILAR API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 31     HPAPI GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 32     HPAPI GLOBAL MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 33     BRANDED HPAPI GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 34     GENERIC HPAPI GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 35     API GLOBAL MARKET REVENUE, BY BUSINESS TYPE, (2017-2025) ($MN)
      • TABLE 36     CAPTIVE API GLOBAL MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 37     CAPTIVE API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 38     BRANDED CAPTIVE API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 39     GENERIC CAPTIVE API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 40     MERCHANT API GLOBAL MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 41     MERCHANT API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 42     BRANDED MERCHANT API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 43     GENERIC MERCHANT API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 44     API GLOBAL MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 45     SYNTHETIC API GLOBAL MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 46     BIOTECH API GLOBAL MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 47     HPAPI GLOBAL MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 48     INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 49     SYNTHETIC INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 50     BIOTECH INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 51     HPAPI INFECTIOUS DISEASES API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 52     ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 53     SYNTHETIC ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 54     BIOTECH ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 55     HPAPI ONCOLOGY API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 56     CARDIOVASCULAR DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 57     SYNTHETIC CARDIOVASCULAR DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 58     BIOTECH CARDIOVASCULAR DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 59     HPAPI CARDIOVASCULAR DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 60     CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 61     SYNTHETIC CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 62     BIOTECH CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 63     HPAPI CENTRAL NERVOUS SYSTEM API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 64     PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 65     SYNTHETIC PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 66     BIOTECH PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 67     HPAPI PULMONARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 68     GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 69     SYNTHETIC GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 70     BIOTECH GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 71     HPAPI GASTROINTESTINAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 72     ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 73     SYNTHETIC ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 74     BIOTECH ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 75     HPAPI ENDOCRINE DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 76     METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 77     SYNTHETIC METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 78     BIOTECH METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 79     HPAPI METABOLIC DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 80     GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 81     SYNTHETIC GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 82     BIOTECH GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 83     HPAPI GENITOURINARY DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 84     MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 85     SYNTHETIC MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 86     BIOTECH MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 87     HPAPI MUSCULOSKELETAL DISORDERS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 88     OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 89     SYNTHETIC OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 90     BIOTECH OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 91     HPAPI OTHER APPLICATIONS API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 92     API GLOBAL MARKET REVENUE, BY REGION, (2017-2025) ($MN)
      • TABLE 93     NORTH AMERICA API MARKET REVENUE, BY SYNTHESIS, (2017-2025) ($MN)
      • TABLE 94     NORTH AMERICA BIOTECH API MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 95     NORTH AMERICA SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 96     NORTH AMERICA BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 97     NORTH AMERICA HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 98     NORTH AMERICA API MARKET REVENUE, BY BUSINESS TYPE, (2017-2025) ($MN)
      • TABLE 99     NORTH AMERICA CAPTIVE API MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 100     NORTH AMERICA MERCHANT API MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 101     NORTH AMERICA API MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 102     NORTH AMERICA SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 103     NORTH AMERICA BIOTECH API MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 104     NORTH AMERICA HPAPI MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 105     NORTH AMERICA API MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
      • TABLE 106     EUROPE API MARKET REVENUE, BY SYNTHESIS, (2017-2025) ($MN)
      • TABLE 107     EUROPE BIOTECH API MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 108     EUROPE SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 109     EUROPE BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 110     EUROPE HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 111     EUROPE API MARKET REVENUE, BY BUSINESS TYPE, (2017-2025) ($MN)
      • TABLE 112     EUROPE CAPTIVE API MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 113     EUROPE MERCHANT API MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 114     EUROPE API MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 115     EUROPE SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 116     EUROPE BIOTECH API MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 117     EUROPE HPAPI MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 118     EUROPE API MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
      • TABLE 119     APAC API MARKET REVENUE, BY SYNTHESIS, (2017-2025) ($MN)
      • TABLE 120     APAC BIOTECH API MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 121     APAC SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 122     APAC BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 123     APAC HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 124     APAC API MARKET REVENUE, BY BUSINESS TYPE, (2017-2025) ($MN)
      • TABLE 125     APAC CAPTIVE API MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 126     APAC MERCHANT API MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 127     APAC API MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 128     APAC SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 129     APAC BIOTECH API MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 130     APAC HPAPI MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 131     APAC API MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
      • TABLE 132     ROW API MARKET REVENUE, BY SYNTHESIS, (2017-2025) ($MN)
      • TABLE 133     ROW BIOTECH API MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 134     ROW SYNTHETIC API MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 135     ROW BIOTECH API MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 136     ROW HPAPI MARKET REVENUE, BY CUSTOMER BASE, (2017-2025) ($MN)
      • TABLE 137     ROW API MARKET REVENUE, BY BUSINESS TYPE, (2017-2025) ($MN)
      • TABLE 138     ROW CAPTIVE API MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 139     ROW MERCHANT API MARKET REVENUE, BY TYPE, (2017-2025) ($MN)
      • TABLE 140     ROW API MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 141     ROW SYNTHETIC API MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 142     ROW BIOTECH API MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 143     ROW HPAPI MARKET REVENUE, BY APPLICATION, (2017-2025) ($MN)
      • TABLE 144     ROW API MARKET REVENUE, BY COUNTRY, (2017-2025) ($MN)
      • TABLE 145     EXPANSIONS (2017-2019)
      • TABLE 146     APPROVALS (2017-2019)
      • TABLE 147     ACQUISITIONS (2017-2019)
      • TABLE 148     AGREEMENTS AND COLLABORATION (2017-2019)
      • TABLE 149     OTHERS (2017-2019)
      • TABLE 150     AUROBINDO PHARMA LIMITED: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 151     AUROBINDO PHARMA LIMITED: TOTAL REVENUE, BY SEGMENT (2015-2017) ($MN)
      • TABLE 152     AUROBINDO PHARMA LIMITED: TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
      • TABLE 153     BOEHRINGER INGELHEIM GMBH: TOTAL REVENUE AND R&D EXPENSES (2015-2017) ($MN)
      • TABLE 154     BOEHRINGER INGELHEIM GMBH TOTAL REVENUE, BY SEGMENTS (2015-2017) ($MN)
      • TABLE 155     BOEHRINGER INGELHEIM GMBH TOTAL REVENUE, BY GEOGRAPHY (2015-2017) ($MN)
      • TABLE 156     CAMBREX: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 157     CAMBREX: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 158     CAMBREX: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 159     DIVIS LABORATORIES LTD: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 160     DIVIS LABORATORIES LTD: TOTAL REVENUE, BY GEOGRAPHY (2016-2018) ($MN)
      • TABLE 161     GSK: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 162     GSK : TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 163     GSK :TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 164     LONZA GROUP: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 165     LONZA GROUP : TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 166     LONZA GROUP :TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 167     THERMO FISHER SCIENTIFIC: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 168     THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY SEGMENT,(2016-2018) ($MN)
      • TABLE 169     THERMO FISHER SCIENTIFIC: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 170     PFIZER INC: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
      • TABLE 171     PFIZER INC: TOTAL REVENUE, BY SEGMENTS, (2016-2018) ($MN)
      • TABLE 172     PFIZER INC: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
      • TABLE 173     SANOFI: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 174     SANOFI: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 175     SANOFI: TOTAL REVENUE, BY GEOGRAPHY (2016-2018) ($MN)
      • TABLE 176     SIEGFRIED HOLDINGS AG: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 177     SIEGFRIED HOLDINGS AG: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 178     SIEGFRIED HOLDINGS AG: TOTAL REVENUE, BY GEOGRAPHY (2016-2018) ($MN)
      • TABLE 179     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 180     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE, BY SEGMENTS (2016-2018) ($MN)
      • TABLE 181     TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE, BY GEOGRAPHY (2016-2018) ($MN)

      LIST OF FIGURES

      • FIGURE 1     API GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: API GLOBAL MARKET
      • FIGURE 3     API GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     API GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     API GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     API GLOBAL MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     API GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 9     API GLOBAL MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     GLOBAL API MARKET SHARE ANALYSIS, 2018 (%)
      • FIGURE 11     GLOBAL API MANUFACTURING LANDSCAPE
      • FIGURE 12     SMALL MOLECULE API PRODUCTION BY APPLICATION (2018), IN-HOUSE V/S CMO (2017 – 2025) (TONS) AND GLOBAL MANUFACTURING CAPACITIES (2018) (LITRES)
      • FIGURE 13     GLOBAL TOTAL API AND CMO PRODUCTION (2017 – 2025) (METRIC TONS)
      • FIGURE 14     PATENT EXPIRY OF SMALL MOLECULES (2016-2021)
      • FIGURE 15     API GLOBAL MARKET SHARE, BY SYNTHESIS (2018 V/S 2025) (%)
      • FIGURE 16     API GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 17     SYNTHETIC API GLOBAL MARKET SHARE, BY REGION (2018 V/S 2025) (%)
      • FIGURE 18     SYNTHETIC API GLOBAL MARKET SHARE, BY CUSTOMER BASE (2018 V/S 2025) (%)
      • FIGURE 19     BIOTECH API GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2018 V/S 2025) (%)
      • FIGURE 20     BIOTECH API GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 21     BIOTECH API GLOBAL MARKET SHARE, BY CUSTOMER BASE (2018 V/S 2025) (%)
      • FIGURE 22     HPAPI GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 23     HPAPI GLOBAL MARKET SHARE, BY CUSTOMER BASE (2018 V/S 2025) (%)
      • FIGURE 24     API GLOBAL MARKET SHARE, BY BUSINESS TYPE (2018 V/S 2025) (%)
      • FIGURE 25     CAPTIVE API GLOBAL MARKET SHARE, BY TYPE (2018 V/S 2025) (%)
      • FIGURE 26     CAPTIVE API GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 27     MERCHANT API GLOBAL MARKET SHARE, BY TYPE (2018 V/S 2025) (%)
      • FIGURE 28     MERCHANT API GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 29     API GLOBAL MARKET SHARE, BY APPLICATION (2018 V/S 2025) (%)
      • FIGURE 30     SYNTHETIC API GLOBAL MARKET SHARE, BY APPLICATION (2018 V/S 2025) (%)
      • FIGURE 31     BIOTECH API GLOBAL MARKET SHARE, BY APPLICATION (2018 V/S 2025) (%)
      • FIGURE 32     HPAPI GLOBAL MARKET SHARE, BY APPLICATION (2018 V/S 2025) (%)
      • FIGURE 33     CARDIOVASCULAR DISORDERS API GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 34     PULMONARY DISORDERS API GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 35     SYNTHETIC PULMONARY DISORDERS API GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 36     BIOTECH PULMONARY DISORDERS API GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 37     HPAPI PULMONARY DISORDERS API GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 38     HPAPI GENITOURINARY DISORDERS API GLOBAL MARKET SHARE, BY REGION, (2018 V/S 2025) (%)
      • FIGURE 39     API GLOBAL MARKET REVENUE, BY REGION (2017-2025) ($MN), CAGR (%)
      • FIGURE 40     API GLOBAL MARKET SHARE, BY GEOGRAPHY (2018) (%)
      • FIGURE 41     NORTH AMERICA API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY TYPE (2018 V/S 2025) (%)
      • FIGURE 42     NORTH AMERICA SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2018 V/S 2025) (%)
      • FIGURE 43     NORTH AMERICA API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2018 V/S 2025) (%)
      • FIGURE 44     NORTH AMERICA API MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 45     NORTH AMERICA SYNTHETIC API MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 46     NORTH AMERICA BIOTECH API MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 47     NORTH AMERICA HPAPI MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 48     NORTH AMERICA API SHARE, BY COUNTRY (2018 V/S 2025) (%)
      • FIGURE 49     U.S. API MARKET REVENUE, BY SYNTHESIS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 50     U.S. API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 51     U.S. SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 52     U.S. BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 53     U.S. HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 54     REST OF N.A. API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 55     REST OF N.A. API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 56     REST OF N.A. SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 57     REST OF N.A. BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 58     REST OF N.A. HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 59     EUROPE API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY TYPE (2018 V/S 2025) (%)
      • FIGURE 60     EUROPE SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2018 V/S 2025) (%)
      • FIGURE 61     EUROPE API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2018 V/S 2025) (%)
      • FIGURE 62     EUROPE API MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 63     EUROPE SYNTHETIC API MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 64     EUROPE BIOTECH API MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 65     EUROPE HPAPI MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 66     EUROPE API SHARE, BY COUNTRY (2018 V/S 2025) (%)
      • FIGURE 67     ITALY API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 68     ITALY API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 69     ITALY SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 70     ITALY BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 71     ITALY HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 72     GERMANY API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 73     GERMANY API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 74     GERMANY SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 75     GERMANY BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 76     GERMANY HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 77     FRANCE API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 78     FRANCE API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 79     FRANCE SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 80     FRANCE BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 81     FRANCE HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 82     REST OF EUROPE API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 83     REST OF EUROPE API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 84     REST OF EUROPE SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 85     REST OF EUROPE BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 86     REST OF EUROPE HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 87     APAC API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY TYPE (2018 V/S 2025) (%)
      • FIGURE 88     APAC SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2018 V/S 2025) (%)
      • FIGURE 89     APAC API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2018 V/S 2025) (%)
      • FIGURE 90     APAC API MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 91     APAC SYNTHETIC API MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 92     APAC BIOTECH API MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 93     APAC HPAPI MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 94     REST OF APAC API SHARE, BY COUNTRY (2018 V/S 2025) (%)
      • FIGURE 95     CHINA API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 96     CHINA API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 97     CHINA SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 98     CHINA BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 99     CHINA HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 100     JAPAN API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 101     JAPAN API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 102     JAPAN SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 103     JAPAN BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 104     JAPAN HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 105     INDIA API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 106     INDIA API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 107     INDIA SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 108     INDIA BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 109     INDIA HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 110     REST OF APAC API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 111     REST OF APAC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 112     REST OF APAC SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 113     REST OF APAC BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 114     REST OF APAC HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 115     ROW API MARKET SHARE, BY SYNTHESIS AND BIOTECH API MARKET, BY TYPE (2018 V/S 2025) (%)
      • FIGURE 116     ROW SYNTHETIC API, BIOTECH API AND HPAPI MARKET SHARE, BY CUSTOMER BASE (2018 V/S 2025) (%)
      • FIGURE 117     ROW API MARKET SHARE, BY BUSINESS TYPE, CAPTIVE API AND MERCHANT API MARKET, BY TYPE (2018 V/S 2025) (%)
      • FIGURE 118     ROW API MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 119     ROW SYNTHETIC API MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 120     ROW BIOTECH API MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 121     ROW HPAPI MARKET SHARE, BY APPLICATION (2018) (%), CAGR (%)
      • FIGURE 122     ROW API SHARE, BY COUNTRY (2018 V/S 2025) (%)
      • FIGURE 123     BRAZIL API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 124     BRAZIL API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 125     BRAZIL SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 126     BRAZIL BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 127     BRAZIL HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 128     REST OF LATAM API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 129     REST OF LATAM API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 130     REST OF LATAM SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 131     REST OF LATAM BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 132     REST OF LATAM HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 133     MIDDLE EAST & OTHERS API MARKET REVENUE, BY BUSINESS TYPE, BIOTECH API MARKET REVENUE, BY TYPE AND API MARKET, BY BUSINESS TYPE (2018 V/S 2025) ($MN)
      • FIGURE 134     MIDDLE EAST & OTHERS API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 135     MIDDLE EAST & OTHERS SYNTHETIC API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 136     MIDDLE EAST & OTHERS BIOTECH API MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 137     MIDDLE EAST & OTHERS HPAPI MARKET REVENUE, BY APPLICATION (2018) ($MN), CAGR (%)
      • FIGURE 138     KEY GROWTH STRATEGIES, (2017-2018)
      • FIGURE 139     SWOT: AMRI
      • FIGURE 140     SWOT: AUROBINDO PHARAMA LIMITED.
      • FIGURE 141     SWOT: BOEHRINGER INGELHEIM GMBH
      • FIGURE 142     SWOT: CAMBREX CORPORATION
      • FIGURE 143     SWOT: DIVIS LABORATORIES
      • FIGURE 144     SWOT: GLAXOSMITHKLINE PLC
      • FIGURE 145     SWOT: LONZA GROUP
      • FIGURE 146     SWOT: OLON S.P.A
      • FIGURE 147     SWOT: PATHEON N.V.
      • FIGURE 148     SWOT: PFIZER INC.
      • FIGURE 149     SWOT: SANOFI
      • FIGURE 150     SWOT: SIEGFRIED HOLDINGS A.G.
      • FIGURE 151     SWOT: TEVA PHARMACEUTICAL INDUSTRIES LTD.

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     AARTI DRUGS LTD
      • 2     AASH BIOTECH PVT LTD.
      • 3     ABBVIE
      • 4     ABC INTERNATIONAL PHARMA SRL.
      • 5     ABCLONAL
      • 6     J.H WHITNEY CAPITAL PARTNERS LLC (ACCUPAC, INC.)
      • 7     ACHAOGEN INC.
      • 8     ACIC PHARMACEUTICAL INC.
      • 9     ADIMMUNE CORPORATION
      • 10     AESICA PHARMACEUTICALS
      • 11     AGC GROUP
      • 12     AGC BIOLOGICS
      • 13     AJANTHA PHARMA
      • 14     AJINOMOTO BIO-PHARMA SERVICES
      • 15     AKORN
      • 16     ALBANY MOLECULAR RESEARCH INC (AMRI)
      • 17     ALBEMARLE CORPORATION
      • 18     ALCAMI CORPORATION
      • 19     ALEMBIC LTD.
      • 20     ALFACHEMICALS
      • 21     ALKEM LABORATORIES LTD.
      • 22     ALKERMES PLC
      • 23     ALLCHEM
      • 24     ALLERGAN PLC
      • 25     ALMAC GROUP
      • 26     ALMELO PRIVATE LIMITED
      • 27     ALPIC REMEDIES
      • 28     ALVEN LABORATORIES
      • 29     AMBIO PHARMA INC.
      • 30     AMEGA BIOTECH
      • 31     AMGEN
      • 32     AMNEAL PHARMACEUTICALS LLC
      • 33     AMOYTOP BIOTECH
      • 34     AMPAC FINE CHEMICALS
      • 35     ANGELINI ACRAF S.P.A.
      • 36     APICORE US LLC
      • 37     APOTEX FERMENTATION INC
      • 38     AQVIDA GMBH
      • 39     ARENA PHARMACEUTICALS
      • 40     ARENE LIFESCIENCES LIMITED
      • 41     AREVIPHARMA GMBH
      • 42     ARISTON PHARMA NOVATECH PVT., LTD.
      • 43     ASPIRE LIFESCIENCES PVT., LTD.
      • 44     ASTRAZENECA PLC.
      • 45     AUROBINDO PHARMA LTD.
      • 46     AVRA LABORATORIES PVT., LTD.
      • 47     AZAD PHARMA AG
      • 48     BACHEM HOLDING AG
      • 49     BAL PHARMA LTD.
      • 50     BASF
      • 51     BAXTER INTERNATIONAL INC.
      • 52     BAYER PHARMA CHEMICALS
      • 53     BIOCODEX S.A.
      • 54     BIOCON LTD.
      • 55     BIOGEN
      • 56     BIOMAX PHARMA
      • 57     BIOMERIN PHARMACEUTICAL INC.
      • 58     BIOPHORE INDIA PHARMACEUTICALS PVT., LTD.
      • 59     BIOSORTIA PHARMACEUTICALS
      • 60     BIOTECHNICA PHARMA GLOBAL
      • 61     BIOVIAN
      • 62     BLANVER FARMOQUIMICA
      • 63     BOEHRINGER INGELHEIM GMBH.
      • 64     BRAMMER BIO
      • 65     BRAWN LABORATORIES LTD.
      • 66     BRISTOL-MYERS SQUIBB
      • 67     CADILA PHARMACEUTICALS LIMITED
      • 68     CAMBREX CORPORATION
      • 69     CATALENT
      • 70     CAYMAN CHEMICALS
      • 71     CELGENE
      • 72     CELLTRION INC.
      • 73     CENTURY PHARMACEUTICALS LTD.
      • 74     CERBIOS-PHARMA SA
      • 75     CFM GROUP (AMSA S.P.A)
      • 76     CHANGZHOU PHARMACEUTICAL FACTORY
      • 77     CHEMCON GMBH
      • 78     CHINA CHEMICAL & PHARMACEUTICAL CO., LTD.
      • 79     CHONGQING HUAPONT PHARMACEUTICAL CO., LTD.
      • 80     CIPLA LIMITED
      • 81     CKD BIO
      • 82     COBA PHARMA
      • 83     CORDEN PHARMA
      • 84     CRYSTALIA
      • 85     CSL LTD
      • 86     CTX LIFESCIENCES
      • 87     DAIICHI SANKYO CHEMICAL PHARMA CO LTD.
      • 88     DAITO PHARMACEUTICAL CO., LTD.
      • 89     DALTON RESEARCH MOLECULE
      • 90     DCS PHARMA AG
      • 91     DISHMAN PHARMACEUTICALS
      • 92     DIVIS LABORATORIES
      • 93     DONG WHA PHARM IND CO LTD.
      • 94     DR.REDDY’S LABORATORIES
      • 95     EIRGEN PHARMA
      • 96     EISAI
      • 97     ELI LILLY PHARMACEUTICALS
      • 98     EMCURE PHARMACEUTICALS LTD.
      • 99     ENALTEC LABS PRIVATE LIMITED.
      • 100     ERCROS
      • 101     ESTECHPHARMA CO., LTD.
      • 102     ESTEVE QUÍMICA
      • 103     EVEREST ORGANICS LIMITED.
      • 104     EVONIK INDUSTRIES AG
      • 105     FAREVA GROUP
      • 106     FARMABIOS
      • 107     FERRING PHARMACEUTICALS
      • 108     FIS FABBRICA ITALIANA SINTETICI S.P.A.
      • 109     FLAMMA S.P.A.
      • 110     FLORENTIS PHARMACEUTICALS PVT., LTD.
      • 111     FORMOSA LABORATORIES INC.
      • 112     FUJI CHEMICAL INDUSTRY CO., LTD.
      • 113     GE HEALTHCARE BIO-SCIENCES AB
      • 114     GENTEC PHARMACEUTICAL GROUP S.A
      • 115     GILEAD SCIENCES, INC.
      • 116     GLAND PHARMA LIMITED.
      • 117     GLAXOSMITHKLINE PLC.
      • 118     GLENMARK GENERICS LTD.
      • 119     GNOSIS S.P.A.
      • 120     GRANULES INDIA LTD.
      • 121     GVK INDUSTRIES LIMITED (GVK BIOSCIENCE)
      • 122     HAOYUAN CHEMEXPRESS CO.LTD.
      • 123     HARMAN FINOCHEM LIMITED.
      • 124     HENI CHEMICAL INDUSTRIES
      • 125     HERAUES HOLDING GMBH
      • 126     HETERO LABS LTD.
      • 127     HIKMA PHARMACEUTICALS
      • 128     HONOUR LAB LTD.
      • 129     HOVIONE
      • 130     HUVAPHARMA
      • 131     HYBIO PHARMACEUTICAL CO., LTD.
      • 132     IBIO INC
      • 133     ICROM S.P.A.
      • 134     INABATA PHARMASYNTHESE
      • 135     INALCO PHARMACEUTICALS
      • 136     INDENA
      • 137     INSIGHT BIOPHARMACEUTICAL
      • 138     INTAS PHARMACEUTICALS LTD.
      • 139     INTERQUIM, S.A.
      • 140     JEIL PHARMACEUTICAL CO. LTD.
      • 141     JOHNSON AND JOHNSON (JANSSEN PHARMACEUTICA NV, BELGIUM)
      • 142      JUBILANT LIFESCIENCES (JUBILANT GENERICS LTD.)
      • 143     KATSURA CHEMICAL CO.,LTD.
      • 144     KERN PHARMA, S.L.
      • 145     KLEOS PHARMA
      • 146     KONGO YAKUHIN CO., LTD.
      • 147     KOSHER PHARMACEUTICALS
      • 148     KRKA PHARMACEUTICALS
      • 149     KYOWA HAKKO KIRIN
      • 150     OFICHEM BV
      • 151     LANNETT CO. INC.
      • 152     LAURUS LABS.
      • 153     LEBSA
      • 154     LGM PHARMA.
      • 155     LIBBS
      • 156     LIPTIS PHARMACEUTICALS
      • 157     LONZA GROUP
      • 158     LOTUS PHARMACEUTICAL CO., LTD.
      • 159     LUPIN
      • 160     LUSOCHIMICA S.P.A
      • 161     MACLEODS PHARMACEUTICAL LTD.
      • 162     MAGLE CHEMOSWED AB
      • 163     MALLINCKRODT PHARMACEUTICALS
      • 164     MEDICHEM S.A
      • 165     MEGAFINE PHARMA LTD
      • 166     MEHTA API
      • 167     MERCK GROUP (MERCK KGAA)
      • 168     METROCHEM API
      • 169     MICRO LABS LTD.
      • 170     MINAKEM S.A.
      • 171     MOEHS IBERICA S.L.
      • 172     MOLCAN CORPORATION
      • 173     MOREPEN
      • 174     MSN ORGANICS PVT, LTD.
      • 175     MYLAN N.V
      • 176     NANOMEDEX PHARMACEUTICALS
      • 177     NATCO PHARMA LTD.
      • 178     NEOVACS KINOID
      • 179     NEULAND LABORATORIES LTD.
      • 180     NEURAXPHARM ARZNEIMITTEL (INKE)
      • 181     NIFTY LABS PVT LTD.
      • 182     NORCHIM
      • 183     NOVARTIS AG
      • 184     NOVASEP
      • 185     NOVO NORDISK
      • 186     NOVOCAP,
      • 187     OLAINFARM JSC.
      • 188     OLON S.P.A.
      • 189     ONCOBIOLOGICS
      • 190     OPTIMUS DRUGS PRIVATE LTD.
      • 191     ORCHID CHEMICALS & PHARMACEUTICALS LTD.
      • 192     ORION (FERMION)
      • 193     PARATEK PHARMACEUTICAL
      • 194     PCAS
      • 195     PELLETS PHARMA LIMITED
      • 196     PERRIGO
      • 197     PFIZER
      • 198     PFANSTIEHL
      • 199     PHARMISPANIA
      • 200     PHYTON BIOTECH LLC
      • 201     PIERRE FABRE
      • 202     PIRAMAL ENTERPRISES LTD.
      • 203     POLPHARMA B2B
      • 204     PRAJNA GENERICS PVT. LTD.
      • 205     PRECISE GROUP
      • 206     PROBIOGEN AG
      • 207     PRINCETON BIOMOLECULAR RESEARCH, INC.
      • 208     RABLON HEALTHCARE PVT LTD.
      • 209     RAKS PHARMA PVT LTD.
      • 210     RECIPHARM AB
      • 211     REGENERON
      • 212     REINE LIFESCIENCE
      • 213     RELIANCE LIFE SCIENCES PVT., LTD.
      • 214     REVA PHARMA PVT., LTD.
      • 215     ROCHE
      • 216     ROCHEM INTERNATIONAL INC.
      • 217     RPG LIFE SCIENCES
      • 218     RXN CHEMICALS PVT. LTD.
      • 219     SAAMYA BIOTECH
      • 220     SAJJALA BIO LABS
      • 221     SANDOZ INTERNATIONAL GMBH
      • 222     SANECA PHARMACEUTICALS
      • 223     SANOFI S.A.
      • 224     SCINOPHARM TAIWAN LTD.
      • 225     SERVIER
      • 226     SHENZHEN HAORUI INDUSTRIAL DEV.
      • 227     SHILPA MEDICARE LIMITED
      • 228     SHIONO CHEMICAL CO., LTD.
      • 229     SHIRE PHARMACEUTICALS
      • 230     SHOUYUAN CHEMICAL
      • 231     SHREEJI PHARMA INTERNATIONAL
      • 232     SIEGFRIED HOLDINNGS AG
      • 233     SIGMA-ALDRICH
      • 234     SIGMAPHARM LABORATORIES LLC.
      • 235     SM BIOMED SDN. BHD
      • 236     SMILAX LABORATORIES LIMITED
      • 237     SMS PHARMACEUTICALS LIMITED
      • 238     SOLARA A PHARMA SCIENCES LTD.
      • 239     SRINI PHARMACEUTICALS LTD.
      • 240     STANDARD CHEMICAL & PHARMACEUTICAL CO.
      • 241     STERLING BIOTECH LTD.
      • 242     STRIDES SHASUN LIMITED
      • 243     SUMITOMO DAINIPPON PHARMA CO., LTD.
      • 244     SUN PHARMACEUTICAL INDUSTRIES LTD.
      • 245     SUVEN LIFE SCIENCE LTD.
      • 246     SUZHOU RYWAY BIOTECH
      • 247     SYMBIOTEC PHARMA LAB PVT., LTD
      • 248     SYNERGENE ACTIVE INGREDIENTS PVT, LTD.
      • 249     SYN-TECH CHEM. AND PHARMA.CO., LTD.
      • 250     TAKEDA PHARMACEUTICAL COMPANY LTD.
      • 251     TARO PHARMACEUTICAL INDUSTRIES LTD.
      • 252     TEMAD CO.
      • 253     TETRAPHASE PHARMACEUTICALS
      • 254     TEVA PHARMACEUTICALS INDUSTRIES LTD.
      • 255     THERAPEUTIC MD INC.
      • 256     THERAVANCE BIOPHARMA
      • 257     THERMO FISHER SCIENTIFIC CORPORATION
      • 258     TORRENT PHARMACEUTICALS, LTD.
      • 259     TRIFECTA PHARMACEUTICALS LLC
      • 260     TRIMAX BIO SCIENCES (P) LIMITED
      • 261     UMICORE
      • 262     UNICHEM LABORATORIES LTD.
      • 263     UNION QUIMICO FARMACEUTICA, S.A.
      • 264     UNIQUE BIOTECH LTD.
      • 265     USV LTD.
      • 266     VAISHALI PHARMA LTD.
      • 267     VENUS REMEDIES (VENUS PHARMA GMBH)
      • 268     VERTEX PHARMECEUTICALS
      • 269     VIRUJ PHARMA
      • 270     VIVIMED LABS LTD.
      • 271     WANBURY LTD.
      • 272     WATSON PHARMA PRIVATE LTD.
      • 273     WAVELENGTH PHARMACEUTICALS
      • 274     WELLONA PHARMACEUTICALS
      • 275     WELT CARE LIFESCIENCES PVT., LTD.
      • 276     WOCKHARDT LIMITED
      • 277     WUXI APPTEC (STA PHARMACEUTICAL CO., LTD.)
      • 278     XELLIA PHARMACEUTICALS
      • 279     YABAO PHARMACEUTICAL GROUP CO., LTD.
      • 280     YANGTZE RIVER PHARMACEUTICAL GROUP
      • 281     YUNG ZIP CHEMICAL INDUSTRIAL CO., LTD.
      • 282     ZAMBON GROUP (ZACH)
      • 283     ZCL CHEMICALS LTD.
      • 284     ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
      • 285     ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD.